Rapid onset and offset of the interaction between rifampicin and long-acting cabotegravir/rilpivirine: A pharmacokinetic case report
Abstract
Long-acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49-year-old man with virologically suppressed HIV-1 infection receiving LA CAB/RPV every 8 weeks who was treated with rifampicin 600 mg twice daily combined with levofloxacin for 7 days as methicillin-resistant Staphylococcus aureus eradication therapy. Temporary oral bridging therapy with tenofovir disoproxil fumarate/emtricitabine and dolutegravir was started concurrently. Plasma cabotegravir (CAB) and rilpivirine (RPV) concentrations were measured weekly using validated LC-MS/MS. Prior to rifampicin initiation, plasma concentrations were 2.08 mg/L for CAB and 0.126 mg/L for RPV and therefore well above target Ctrough levels of >0.664 mg/L for CAB and >0.032 mg/L for RPV. After 7 days of rifampicin treatment, concentrations decreased to 0.90 mg/L for CAB and 0.022 mg/L for RPV, corresponding to reductions of 57% and 83%, respectively, with RPV concentrations falling below the proposed therapeutic target. One week after rifampicin discontinuation, concentrations recovered to 1.10 mg/L for CAB and 0.050 mg/L for RPV. The concentrations increased further thereafter without additional drug administration, reflecting continued release from the intramuscular depot. HIV-1 RNA remained undetectable throughout follow-up. The observed…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.